Loading
A phase 1 trial of Zeprumetostat run by Treeline Biosciences, Inc., active and no longer recruiting.
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma is a phase 1 interventional study registered as NCT06733441 by Treeline Biosciences, Inc., with 50 participants planned, started 2024-12-16. Conditions recorded: Lymphoma. Interventions recorded: TLN-254 and TLN-254.
Shares Zeprumetostat, Treeline Biosciences, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Treeline Biosciences, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Zeprumetostat, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Treeline Biosciences and the tag pipeline.
Shares Treeline Biosciences and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/